Most Read Articles
10 Jan 2018
Shared decision support with the use of standardized decision aids improves decision quality and reduces implantation of left ventricular assist device as destination therapy (DT-LVAD) in patients with advanced heart failure.
21 Dec 2017
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.
10 Jan 2018

A new batch of apolipoprotein B (apoB)-lowering drugs that capitalize on statins’ ability to lower lipids will further benefit patients at high cardiovascular (CV) risk who need to be treated more aggressively.

Pearl Toh, 15 Dec 2017
Blood pressure (BP) readings appeared to be similar regardless of whether BP measurements were attended or unattended by staff, nor were CV outcomes different between the two techniques, according to a post hoc survey on participants following the SPRINT* trial.

Triglyceride to HDL-C ratio may predict cardiovascular events in T2DM patients with CAD

26 Sep 2017
A recent study shows that diabetes drugs are not only beneficial for the targeted disease, it can also lower the risk of heart failure and renal disease.

Elevated values of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio appear to predict future cardiovascular events (CVE) in Chinese type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD), a recent study has shown.

The study included 1,447 consecutive T2DM patients with stable CAD, as confirmed by angiography. Over an average follow-up period of 20.3 months, 96 patients had CVEs.

The most common CVE was myocardial revascularization procedures because of clinical deterioration, reported in 57.3 percent (n=55). This was followed by nonfatal myocardial infarction (MI, 19.8 percent; n=19), stroke (15.6 percent; n=15) and cardiac deaths (7.3 percent; n=7).

The log of the TG/HDL-C at baseline was significantly associated with subsequent CVEs (hazard ratio [HR], 2.47; 95 percent CI, 1.01 to 6.04; p=0.047) even after adjusting for other CVD risk factors such as sex, BMI, total cholesterol and blood pressure.

Baseline HbA1c levels were also significantly associated with subsequent CVE development (HR, 1.20; p=0.009) after adjusting for sex and age. When smoking status, total cholesterol and left ventricle ejection fraction were included in the model, the significant association was disrupted.

The study included patients hospitalized for T2DM and had stable CAD. Exclusion criteria included acute coronary syndrome, systemic inflammatory diseases, thyroid dysfunction, renal insufficiency, malignancies and familial hypercholesterolaemia, among others.

For the purposes of the study, CVEs were defined as strokes, cardiac death, coronary artery bypass graft, percutaneous coronary intervention and nonfatal MI.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
10 Jan 2018
Shared decision support with the use of standardized decision aids improves decision quality and reduces implantation of left ventricular assist device as destination therapy (DT-LVAD) in patients with advanced heart failure.
21 Dec 2017
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.
10 Jan 2018

A new batch of apolipoprotein B (apoB)-lowering drugs that capitalize on statins’ ability to lower lipids will further benefit patients at high cardiovascular (CV) risk who need to be treated more aggressively.

Pearl Toh, 15 Dec 2017
Blood pressure (BP) readings appeared to be similar regardless of whether BP measurements were attended or unattended by staff, nor were CV outcomes different between the two techniques, according to a post hoc survey on participants following the SPRINT* trial.